Overall, these proof-of-principle experiments demonstrate the critical role of mitochondrial dynamic dysfunction in CD38-upregulated activity and support use of this approach to prime MM cells to NAD+-lowering agents. This evidence concerns the gene CD38 and Miyoshi myopathy.